U.S. markets closed

OpGen, Inc. (OPGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6800-0.0301 (-4.24%)
At close: 04:00PM EDT
0.6701 -0.01 (-1.46%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close0.7101
Bid0.6676 x 200
Ask0.6893 x 200
Day's Range0.6648 - 0.7001
52 Week Range0.1650 - 3.8400
Avg. Volume1,752,570
Market Cap8.17M
Beta (5Y Monthly)-0.69
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OPGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OpGen, Inc.
    Solid 1Q Leads into 2Q UncertaintyThe Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Laboratory Corp. Of America Hl (LH); Micron Technology Inc. (MU); Oracle Corp. (ORCL); Invesco Ltd (IVZ) and the Focus List deletions are Advanced Micro Devices Inc. (AMD); American Express Co. (AXP); Crowdstrike Holdings Inc (CRWD); Unitedhealth Group Inc (UNH).
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    OpGen Announces Acquisition of Preferred Stock by David Lazar

    David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred St

  • GlobeNewswire

    OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G

  • GlobeNewswire

    OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

    ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to pur